Shanghai Henlius Biotech Co. Ltd.

Sandoz has announced a deal worth up to $301m with Shanghai Henlius Biotech for rights to a Yervoy (ipilimumab) biosimilar in countries around the world. Targeting originator sales of $2.5bn achieved

Roche says the potential for biosimilar competition to its Perjeta (pertuzumab) blockbuster HER2 inhibitor for breast cancer is “not a threat that we’re super worried about right now,” considering the

The European Medicines Agency has started reviewing for potential pan-EU marketing authorization 15 new drugs, including Novo Nordisk’s semaglutide for the treatment of non-cirrhotic metabolic dysfunc

Shanghai Henlius Biotech is trying to play a David versus Goliath game of catch-up with Pfizer, in pursuit of the commercialization of the world’s first PD-L1-targeting antibody-drug conjugate (ADC).